Benevolent - About the company
Benevolent is an acquired company based in Luxembourg (Luxembourg), founded in 2013 by Michael Brennan and Ken Mulvany. It operates as a Developer of artificial intelligence software for pharmaceutical drug discovery research. Benevolent has raised $282M in funding from Woodford Investment Management and Temasek, with last known valuation of £1.67B. The company has 175 active competitors, including 68 funded and 13 that have exited. Its top competitors include companies like Schrodinger, Recursion Pharmaceuticals and XtalPi.
Sectors and market segments that Benevolent operate in
Benevolent serves in the HealthTech, Life Sciences, Native AI market segments.The primary business model of Benevolent are:Company Details
Developer of artificial intelligence software for pharmaceutical drug discovery research. The technology utilizes knowledge graphs and proprietary ontologies to assist scientists in identifying potential therapeutic targets. The platform processes biological and chemical data to support decision making processes within research and development workflows.
- Social
- Phone Number
- +44 **********
- Registered Address
- Brooklyn, New York
Key Metrics
Founded Year
2013
Location
Luxembourg, Luxembourg
Stage
Acquired
Total Funding
$282M in 4 rounds
Latest Funding Round
Last Known Valuation
£1.67B as on Jun 06, 2019
Investors
Ranked
26th among 175 active competitors
Annual Revenue
£5.24M as on Dec 31, 2024
Employee Count
69 as on May 31, 2026
Similar Companies
Exit Details
Acquired by Odyssey Acquisition (Dec 06, 2021)
Legal entities associated with Benevolent
Benevolent is associated with 6 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
BENEVOLENT TECHNOLOGY INC CIN: 814105785 , United States, Active | Dec 26, 999 | - | 19 (As on Dec 31, 2023) | - |
Benevolentai Cambridge Limited CIN: 4977050 , United Kingdom, Active | Nov 25, 2003 | - | - | |
SKYSCANNER LIMITED CIN: 4217916 , Germany, Active | May 15, 2001 | $1.39M (As on Dec 31, 2020) | 749 (As on Dec 31, 2021) | |
BenevolentAI Limited CIN: 9781806 , United Kingdom, Active | Sep 16, 2015 | $6.7M (As on Dec 31, 2024) | 343 (As on Dec 31, 2023) | |
BenevolentAl CIN: B288631 , Luxembourg, Active | May 21, 2020 | - | - | - |
Benevolentai Technology Limited CIN: 9804835 , United Kingdom, Active | Sep 30, 2015 | - | - |
Benevolent's acquisition details
Benevolent got acquired by Odyssey Acquisition on Dec 06, 2021.
Click here to take a look at Benevolent's acquisition in detail
Sign up to download Benevolent's company profile
Benevolent's funding and investors
Benevolent has raised a total funding of $282M over 4 rounds. Its first funding round was on Dec 13, 2013. Its latest funding round was a Series C round on May 07, 2019 for $90M. 1 investor participated in its latest round. Benevolent has 12 institutional investors and 6 angel investors.
Here is the list of recent funding rounds of Benevolent:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 07, 2019 | $90M | Series C | - | - | - | |
Apr 18, 2018 | $115M | Series C | $2.18B | - | - | |
Oct 17, 2014 | $64M | Series B | - | - | - |
Access funding benchmarks and valuations. Sign up today!View details of Benevolent's funding rounds and investors
Benevolent's founders and board of directors
Founder? Claim ProfileThe founders of Benevolent are Michael Brennan and Ken Mulvany. Joerg Moeller is the CEO of Benevolent.
Here are the details of Benevolent's key team members:
- Michael Brennan: Former Co-Founder of Benevolent and founder of 2 other companies, Tootoot and Tootoot. They serve on the board of 1 company.Contact Info: 1 email address
- Ken Mulvany: Co-Founder of Benevolent. They serve on the board of 1 company.Contact Info: 2 email addresses
Benevolent's Board of Directors
Benevolent's board has 3 active members. Michael Brennan and Ken Mulvany are part of team and Jung Park is independent board member.Here is the list of Benevolent's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Team | - | Current | 8y 1m | |
Team | - | Current | 10y 8m | |
Independent board member | - | Current | 6y 6m | |
Independent board member | - | Past | 3y 9m | |
Independent board member | - | Past | 1y 9m | |
Independent board member | - | Past | 0y 8m |
View details of Benevolent's Founder profiles and Board Members
Benevolent's employee count trend
Benevolent has 69 employees as of May 26. Here is Benevolent's employee count trend over the years:
Uncover Benevolent's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Benevolent's Competitors and alternates
Top competitors of Benevolent include Schrodinger, Recursion Pharmaceuticals and XtalPi. Here is the list of Top 10 competitors of Benevolent, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Schrodinger 1990, New York City (United States), Acquired | Provider of a web-based simulation and modelling tool | $162M | 74/100 | |
2nd | Recursion Pharmaceuticals 2013, New York (United States), Public | AI-enabled drug discovery and development platform for novel therapeutics | $452M | 67/100 | |
3rd |  XtalPi 2014, Cambridge (United States), Public | AI-based drug research and development company | $785M | 67/100 | |
4th |  Isomorphic Labs 2021, London (United Kingdom), Series B | Digital platform focused on revolutionizing drug discovery using AI | $2.7B | 64/100 | |
5th | Causaly 2018, London (United Kingdom), Series B | Provider of an AI platform for life sciences and biomedical research | $93M | 63/100 | |
6th |  Xaira 2023, San Francisco (United States), Series D | AI-enabled platform for drug discovery and development | $1B | 63/100 | |
7th |  METiS Therapeutics 2017, Cambridge (United States), Series B | Provider of an AI-assisted platform for drug discovery and development | $252M | 63/100 | |
8th |  Valo Health 2019, Boston (United States), Series B | AI-powered platform for drug discovery and development | $450M | 63/100 | |
9th |  Tandem AI 2021, New York (United States), Series A | AI-based drug discovery tool for researchers | $82M | 62/100 | |
10th |  In Silico 2014, Cambridge (United States), Public | AI-enabled bioinformatics platform for drug discovery and biomarker development | $510M | 62/100 | |
26th | Benevolent 2013, Luxembourg (Luxembourg), Acquired | Developer of artificial intelligence software for pharmaceutical drug discovery research | $282M | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Benevolent's competitors? Click here to see the top ones
Benevolent's Investments and acquisitions
Benevolent has made no investments or acquisitions yet.
News related to Benevolent
Filter this list•
Santhera Announces Chief Financial Officer Transition with Appointment of Catherine IstedGlobeNewswire•Feb 10, 2025•Santhera, Benevolent, ReNeuron Group, Oxford BioMedica and 3 others
•
BenevolentAI to delist from Euronext and merge into Osaka HoldingsNewsnReleases•Feb 06, 2025•Benevolent
•
BenevolentAI to merge with Osaka Holdings; shareholder meeting announced.Business Wire•Feb 06, 2025•Benevolent, Euronext
•
BenevolentAI pivots back to 'TechBio' roots, causing more layoffsFierce Biotech•Dec 11, 2024•Benevolent
•
BenevolentAI Unveils Major Strategic Overhaul With Return to Original MissionBusiness Wire•Dec 11, 2024•Benevolent
•
•
•
BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024Business Wire•Oct 10, 2024•Benevolent
•
BenevolentAI Interim Results for the Six Months Ended 30 June 2024Business Wire•Sep 19, 2024•Benevolent
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Benevolent
Explore our recently published companies
- Indian Institute of Gems and Jewellery - Mumbai based, 2010 founded, Unfunded company
- Frank Capital - United Kingdom based, Unfunded company
- Lovat Parks - London based, 2018 founded, Unfunded company
- Big Penny Social - United Kingdom based, 2022 founded, Unfunded company
- Schuchmannfarms - Clever based, 2024 founded, Funding Raised company
- Millbak - United Kingdom based, Unfunded company
